Organised by China Anti-Cancer Association
Chair
Prof. Mei Dong, China Anti-Cancer Association (CACA) Integrative Oncology Pharmacy Committee and Harbin Medical University Cancer Hospital, China
Introduction
Malignant tumors pose a significant health threat, with 19.29 million new cases and 9.96 million deaths globally in 2020. Despite this, advancements in cancer research and treatment have improved prevention and management. The evolving landscape of cancer care, with innovative drugs and chronic disease management, underscores the growing role of clinical pharmacists in managing cancer patients.
The complexity of cancer, its treatment heterogeneity, and patient health needs demand advanced clinical pharmacy services. This forum will feature experts discussing oncology pharmacy development, anti-cancer drug applications, new drug research, cancer pain, and home care. Renowned pharmacy experts will also engage in discussions.
Clinical pharmacy, linking medicine and pharmaceuticals, is crucial in cancer prevention and treatment. Oncology pharmacists, in collaboration with medical teams, prioritize health and well-being, addressing the increasing health demands of the public.
Programme:
| 13:00 – 13:10 | Chair introduction & Welcome speech |
| Prof. Mei Dong, China Anti-Cancer Association (CACA) Integrative Oncology Pharmacy Committee and Harbin Medical University Cancer Hospital, China | |
| Prof Robert Moss, Vice President, FIP, The Netherlands | |
| 13:10 – 13:20 | Vasculogenic mimicry mediated by IGF2BP3/HDLBP-Enhanced cotranslational translocation promotes anti-angiogenic therapy resistance in triple-negative breast cancer |
| Prof. Jifu Wei, Jiangsu Cancer Hospital, Nanjing, China | |
| 13:20 – 13:30 | Pharmacist-integrated MDT clinic for gastrointestinal stromal tumours （GIST): Clinical practice and outcomes |
| Prof. Wanyi Chen, Chongqing University Cancer Hospital, Chongqing, China | |
| 13:30 – 13:40 | Introduction to the whole process of pharmaceutical care for cancer patients |
| Prof. Xiaoyu Li, Zhongshan Hospital, Fudan University, Shanghai, China | |
| 13:40 – 13:45 | Xihuang Wan combined with PD-1 inhibitors in lung cancer: Preliminary evidence for enhanced efficacy and attenuation of immune-related myocarditis |
| Dr. Chunyu Li, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China | |
| 13:45 – 13:50 | Cardiovascular implications of tumour immunotherapy: A pharmaceutical perspective |
| Prof. Shuai Jiang, Harbin Medical University Cancer Hospital, Harbin, China | |
| 13:50 – 13:55 | Challenges and obstacles in the clinical implementation of antitumor drugs' TDM |
| Dr. Zaiwei Song, Peking University Third Hospital, Beijing, China | |
| 13:55 – 14:00 | Closing |
Learning objectives:
1. Hospital management and rational application of anti-tumor drugs.
2. Research and development of clinical pharmacy of anti-tumor drugs.
3. Clinical pharmacists participate in the practice exchange of clinical application of anti-tumor drugs.
Take home messages:
1. Establish evidence-based hospital protocols for anti-tumor drug management to ensure safe, cost-effective, and rational clinical application.
2. Advance Translational Research: Drive precision medicine through clinical pharmacy R&D—focusing on pharmacogenomics, TDM, and resistance mechanisms—to personalize anti-tumor therapies.
3. Integrate Pharmacists in Multidisciplinary Practice: Actively engage clinical pharmacists in tumor boards and peer exchanges to enhance medication decision-making, toxicity management, and standardized care.
